

## 1 **Extended Methods**

### 2 *Study design and enrollment*

3 The PREVenT-COVID study is a Canadian prospective study of vaccine immunogenicity in  
4 SOTRs across seven tertiary care transplant centres<sup>9</sup>. This study of cell-mediated immunity was  
5 conducted at the University of British Columbia (UBC) with approval from the UBC Research  
6 Ethics Board (H21-01269). All participants provided informed consent. Adult outpatient SOTRs  
7 at least 1 month post-transplant and taking at least one immunosuppressive therapeutic were  
8 enrolled at first dose of an approved COVID-19 mRNA vaccine, Pfizer-BioNTech BNT162b2 or  
9 Moderna mRNA-1273, beginning January 2021. Patients who reported a febrile illness in the  
10 past week, active cytomegalovirus viremia, use of rituximab in the past 6 months, or current  
11 intravenous immunoglobulin or acute rejection therapy were excluded. Whole blood was drawn  
12 from participants within 2 weeks prior to the 2<sup>nd</sup> vaccine dose, 3-6 weeks post-1<sup>st</sup> dose, 6 months  
13 post-1<sup>st</sup> dose, 3-6 weeks post-3<sup>rd</sup> dose and 1 year post-1<sup>st</sup> dose. 1-year samples served as post-  
14 fourth dose (3-6 weeks) samples in a subset of patients. PBMCs were collected from blood  
15 samples and cryopreserved at -80°C. Participants were to inform the study team if they  
16 developed COVID-19, for confirmation via PCR or rapid antigen test.

### 17 *SARS-CoV-2 ancestral and Omicron BA.4/5 Spike peptides*

18 SARS-CoV-2 ancestral strain (PM-WCPV-S-1, JPT) and Omicron BA.4/5 (PM-SARS2-  
19 SMUT10-1, JPT) peptide pools (15-mers overlapping by four amino acids) corresponding to the  
20 complete Spike proteins were aliquoted in 30% DMSO and stored at -80°C.

### 21 *SARS-CoV-2 ancestral and XBB.1.5 Spike proteins*

22 The HexaPro expression plasmid was a gift from Jason McLellan (Addgene plasmid #154754;  
23 <http://n2t.net/addgene:154754>; RRID: Addgene\_154754) which was used to construct the  
24 D614G mutant via site-directed mutagenesis (Q5 Site-Directed Mutagenesis Kit, New England  
25 Biolabs). The XBB.1.5 HexaPro S protein gene was synthesized and inserted into pcDNA3.1  
26 (GeneArt Gene Synthesis, Thermo Fisher Scientific). Expi293F cells (Thermo Fisher, Cat#  
27 A14527) were grown in suspension culture using Expi293 Expression Medium (Thermo Fisher,  
28 Cat# A1435102) at 37 °C, 8% CO<sub>2</sub>. Cells were transiently transfected at a density of 3 × 10<sup>6</sup>  
29 cells/mL using linear polyethylenimine (Polysciences Cat# 23966-1). The media was  
30 supplemented 24 h after transfection with 2.2 mM valproic acid, and expression was carried out  
31 for 3–7 days at 37 °C, 8% CO<sub>2</sub>.

32  
33  
34 To purify spike protein ectodomains, supernatant was loaded onto a 5 mL HisTrap excel column  
35 (Cytiva). The column was washed for 20 column volumes (CVs) with wash buffer (20 mM Tris  
36 pH 8.0, 500 mM NaCl), 5 CVs of wash buffer supplemented with 20 mM imidazole, and the  
37 protein eluted with elution buffer (20 mM Tris pH 8.0, 500 mM NaCl, 500 mM imidazole).  
38 Elution fractions containing the protein were pooled and concentrated (Amicon Ultra 100 kDa  
39 cut off, Millipore Sigma) for gel filtration. Gel filtration was conducted using a Superose 6  
40 10/300 GL column (Cytiva) pre-equilibrated with GF buffer (20 mM Tris pH 8.0, 150 mM  
41 NaCl). Peak fractions corresponding to soluble protein were pooled and concentrated (Amicon  
42 Ultra 100 kDa cut off, Millipore Sigma) Protein samples were flash-frozen in liquid nitrogen and  
43 stored at -80°C.

44

45 *Activation-induced marker assays*

46 Cryopreserved PBMCs were thawed into 37°C Immunocult XF (10981, STEMCELL) with 1%  
47 penicillin/streptomycin and 50 U/mL benzonase (70664-3, Novagen). PBMCs were rested  
48 overnight at 37°C in Immunocult XF with 1% penicillin/streptomycin. For ancestral and BA.4/5  
49 peptide-based assays, PBMCs were stimulated for 20 h at  $4\text{-}5 \times 10^5$  cells per condition in 200  $\mu\text{L}$   
50 wells of a 96-well U-bottom plate with 1  $\mu\text{g}/\text{mL}$  SARS-CoV-2 ancestral strain or Omicron  
51 BA.4/5 peptides. Cytostim (0.05%) (130-092-172, Miltenyi) and equimolar (0.12%) DMSO  
52 were used as positive and negative controls, respectively, and an influenza vaccine (2.5%)  
53 (Fluzone® Quadrivalent, Sanofi-Pasteur) stimulation was used as an assay control. For ancestral  
54 and XBB.1.5 protein-based assays, stimulation was performed with whole protein isolates at 0.5  
55  $\mu\text{g}/\text{mL}$  for 44 h, using an equivolumetric PBS as a negative control, 1  $\mu\text{g}/\text{mL}$  ancestral strain  
56 peptides as an assay control and 0.05% Cytostim as a positive control.

57

58 CD4 and CD107a staining antibodies were added during stimulation, while surface staining for  
59 CD3, CD4, CD8, CD25, CD69, CD134, and CD137 was performed after the stimulation period.  
60 Data were acquired on an LSR Fortessa (BD) flow cytometer on high-throughput sampler (HTS)  
61 mode. Antigen-specific CD4<sup>+</sup> T cells were defined as CD134<sup>+</sup>/CD25<sup>+</sup>, CD134<sup>+</sup>/CD69<sup>+</sup> or  
62 CD137<sup>+</sup>/CD69<sup>+</sup> while antigen-specific CD8<sup>+</sup> T cells were defined as CD107a<sup>+</sup>/CD69<sup>+</sup>,  
63 CD107a<sup>+</sup>/CD137<sup>+</sup> or CD137<sup>+</sup>/CD69<sup>+</sup>, using widely reported markers<sup>23,36-44</sup>.

64

65 *Data Analysis*

66 Data were analyzed using FlowJo v10.8.1 and GraphPad Prism v10.0.0. Antigen-specific T cells  
67 were quantified as the percentage of CD4<sup>+</sup> or CD8<sup>+</sup> T cells expressing each AIM marker, after  
68 subtracting the equivalent frequency of AIM<sup>+</sup> cells in the unstimulated condition. AIM  
69 frequencies less than 0.005%, considered the limit of detection for the assay, were set to equal  
70 0.005% to avoid negative or zero values. Samples with fewer than 10 000 total CD4<sup>+</sup> or CD8<sup>+</sup>  
71 cells were excluded from analyses. AIM responses were compared across timepoints using a  
72 mixed-effects analysis (REML) on log<sub>2</sub>-transformed data with the assumption of sphericity,  
73 followed by post-hoc Dunnett's multiple comparisons test. Patients who received a fourth dose  
74 or contracted COVID-19 were excluded from this analysis.

75

76 Wilcoxon signed-rank tests were used to compare 1-year to post-3<sup>rd</sup> dose responses between  
77 post-fourth dose (within 3-6 weeks), control (neither received fourth dose nor contracted  
78 COVID-19) and hybrid (fourth dose and contracted COVID-19) groups. Changes from post-third  
79 dose between groups were compared using a Kruskal-Wallis test with Dunn's multiple  
80 comparisons. Responses to the ancestral strain and Omicron BA.4/5, as well as responses to the  
81 ancestral strain and XBB.1.5, were compared by Wilcoxon signed-rank test on post-3<sup>rd</sup> dose  
82 AIM<sup>+</sup> frequencies. Median post-3<sup>rd</sup> dose AIM responses between groups defined by clinical  
83 parameters were compared using Mann-Whitney and Kruskal-Wallis (with Dunn's multiple  
84 comparisons) tests as appropriate. Semilogarithmic regression analysis was performed to model  
85 the continuous effects of age and time since transplantation on post-3<sup>rd</sup> dose AIM responses,  
86 testing the null hypothesis of slope being equal to zero.

87

88 Spearman's correlations were used to assess relationships between post-third dose T cell AIM  
89 responses and previously published serum anti-RBD titres from the same individuals<sup>9</sup>. In patients

90 with undetectable anti-RBD antibodies post-second dose, log-log regression was used to assess  
91 the relationship between post-second dose T cell AIM responses and subsequent development of  
92 post-third dose antibody titres. Post-third dose AIM responses to BA.4/5 were also compared  
93 between individuals with and without detectable BA.4/5 neutralization titres<sup>9</sup>.  
94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115


116

117

118

119

# Figure S1



121

122


123 **Figure S1. Cohort overview.** Solid-organ transplant recipients (SOTRs) were recruited for the  
 124 cellular immunity substudy from the University of British Columbia (UBC) PREVenT cohort (n  
 125 = 80). Four SOTRs did not consent or withdrew consent. The remaining SOTRs were enrolled  
 126 (PBMCs collected) at pre-second dose, post-second dose or post-third dose timepoints until  
 127 PBMCs from over half of each organ group (kidney, liver or lung recipients) had been collected.  
 128 The final sample size (n = 42) thus included 16 kidney recipients, 16 liver recipients and 10  
 129 recipients.

130


131

# Figure S2

## A



## B






132

133

134 **Figure S2. Representative gating strategy.** Example flow cytometry data are shown for  
 135 PBMCs from SOTRs following a 20 h stimulation with **A)** DMSO (0.12%) and **B)** Cytostim  
 136 (0.05%). Activation-induced marker (AIM)+ cell frequencies were measured within live CD4+  
 137 or CD8+ single cell populations. AIM+ CD4+ T cells were defined as co-expressing CD134 and  
 138 CD25, CD134 and CD69 or CD137 and CD69. AIM+ CD8+ T cells were defined as co-  
 139 expressing CD107a and CD69, CD107a and CD137 or CD137 and CD69. The Cytostim-  
 140 stimulated positive control for each sample was used to define the respective AIM+ population  
 141 for each AIM.

142


**Figure S3**



144 **Figure S3. The activation-induced marker assay is specific to SARS-CoV-2.** PBMCs from  
 145 solid organ transplant recipients (SOTRs, n = 42) vaccinated with COVID-19 mRNA vaccines  
 146 were stimulated with 2.5% Fluzone® Quadrivalent influenza vaccine (Sanofi-Pasteur) as an  
 147 irrelevant antigen control. **A)** Representative flow cytometry data showing CD4+ and CD8+ T  
 148 cell activation-induced marker (AIM) responses. Influenza-specific CD4+ **(B)** and CD8+ **(C)** T  
 149 cell activation-induced marker responses at pre-second dose, post-second dose, six months post-  
 150 first dose, post-third dose and one year post-first dose throughout the COVID-19 vaccination  
 151 schedule. All data are shown as AIM+ frequencies after subtracting the equivalent AIM+  
 152 frequency in the DMSO-stimulated control. SOTRs who received a fourth dose or contracted  
 153 COVID-19 before the one year timepoint were included.

154  
 155  
 156  
 157  
 158  
 159  
 160  
 161  
 162


## Figure S4



163  
 164

165 **Figure S4. The activation-induced marker assay demonstrates low technical variability**  
 166 **over time.** Representative PBMCs from two healthy donors used as batch controls display  
 167 consistent activation-induced marker responses over time when stimulated with 0.05% Cytostim  
 168 (anti-CD3/CD28) (Miltenyi).

# Figure S5



169

170 **Figure S5. Relationships of T cell activation-induced marker responses with sex and**  
 171 **vaccine type in solid organ transplant recipients.** Post-third dose PBMCs from solid organ  
 172 transplant recipients vaccinated with COVID-19 mRNA vaccines were stimulated with 1  $\mu\text{g/mL}$   
 173 SARS-CoV-2 ancestral or Omicron BA.4/5 Spike peptides for 20 h. Activation-induced marker  
 174 (AIM) responses were quantified by flow cytometry as frequencies of CD134+/CD69+ or  
 175 CD137+/CD69+ events among CD4+ and CD8+ T cells, respectively, after subtracting the  
 176 equivalent frequency in the DMSO-stimulated control. **A)** AIM responses in male (blue circles,  
 177  $n = 14$ ) and female (red squares,  $n = 19$ ) patients were compared using a Mann-Whitney U-test.  
 178 **B)** AIM responses in patients who had received Pfizer-BioNTech BNT162b2 (Pfizer, blue  
 179 circles,  $n = 27$ ) or Moderna mRNA-1273 (Moderna, red squares,  $n = 6$ ) vaccines for at least two  
 180 of three doses were compared using a Mann-Whitney U-test.